Clinical Trial Detail

NCT ID NCT03504410
Title Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone vs HD Cytarabine and Mitoxantrone in Older Patients With R/R AML
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Rafael Pharmaceuticals Inc.
Indications

acute myeloid leukemia

Therapies

Cytarabine + Mitoxantrone

CPI-613 + Cytarabine + Mitoxantrone

Age Groups: adult senior

No variant requirements are available.